References in periodicals archive ?
For example, as noted earlier, the small fraction of NSCLC patients carrying a chromosome rearrangement resulting from an ALK mutation will have a poor outcome with conventional therapy but will do well with a personalized treatment that includes Xalkori, which is ineffective in a majority of NSCLS patients.
Among the topics are tumor micro-environment, racial and ethnic diversity, chemoradiotherapy for inoperable non-small cell lung cancer (NSCLS), epidermal growth factor receptor inhibitors in treating NSCLS.
The study analyzed progression-free survival and overall survival among 663 patients with advanced NSCLS whose cancer was stable following treatment with a platinum-contain drug (such as cisplatin or carboplatin); 441 patients were randomly assigned to receive pemetrexed, and 22 patients received a placebo.
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLS).
2: Graph below showing the 2 most common histological types seen among the female lung carcinoma patient Histological type NSCLS 80.11% SCLC 3.31% Note: Table made from pie chart.
Acronyms browser ?
Full browser ?